RT Journal Article
SR Electronic
T1 Direct detection of SARS-CoV-2 using CRISPR-Cas13a and a mobile phone
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20201947
DO 10.1101/2020.09.28.20201947
A1 Parinaz Fozouni
A1 Sungmin Son
A1 María Díaz de León Derby
A1 Gavin J. Knott
A1 Carley N. Gray
A1 Michael V. D’Ambrosio
A1 Chunyu Zhao
A1 Neil A. Switz
A1 G. Renuka Kumar
A1 Stephanie I. Stephens
A1 Daniela Boehm
A1 Chia-Lin Tsou
A1 Jeffrey Shu
A1 Abdul Bhuiya
A1 Max Armstrong
A1 Andrew Harris
A1 Jeannette M. Osterloh
A1 Anke Meyer-Franke
A1 Charles Langelier
A1 Katherine S. Pollard
A1 Emily D. Crawford
A1 Andreas S. Puschnik
A1 Maira Phelps
A1 Amy Kistler
A1 Joseph L. DeRisi
A1 Jennifer A. Doudna
A1 Daniel A. Fletcher
A1 Melanie Ott
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.28.20201947.abstract
AB The December 2019 outbreak of a novel respiratory virus, SARS-CoV-2, has become an ongoing global pandemic due in part to the challenge of identifying symptomatic, asymptomatic and pre-symptomatic carriers of the virus. CRISPR-based diagnostics that utilize RNA and DNA-targeting enzymes can augment gold-standard PCR-based testing if they can be made rapid, portable and accurate. Here we report the development of an amplification-free CRISPR-Cas13a-based mobile phone assay for direct detection of SARS-CoV-2 from nasal swab RNA extracts. The assay achieved ∼100 copies/μL sensitivity in under 30 minutes and accurately detected a set of positive clinical samples in under 5 minutes. We combined crRNAs targeting SARS-CoV-2 RNA to improve sensitivity and specificity, and we directly quantified viral load using enzyme kinetics. Combined with mobile phone-based quantification, this assay can provide rapid, low-cost, point-of-care screening to aid in the control of SARS-CoV-2.Competing Interest StatementP.F., S.S., G.J.K, J.A.D., D.A.F., and M.O. have filed patent applications related to this work. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners and Roche.Funding StatementWe gratefully acknowledge support from the NIH (grant 5R61AI140465-03 to J.A.D., D.A.F., and M.O.). This project is supported by the NIH Rapid Acceleration of Diagnostics (RADx) program and has been funded in whole or in part with Federal funds from National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Grant No. 3U54HL143541- 02S1. P.F. was supported by the UCSF Medical Scientist Training Program (T32GM007618) and the NIH/NIAID (F30AI143401). M.D.L.D was supported by the UC MEXUS-CONACYT Doctoral Fellowship. G.J.K. is supported by an NHMRC Investigator Grant (EL1, APP1175568) and previously an American Australian Association Fellowship. J.A.D. is an HHMI Investigator. We are grateful for philanthropic support from the James B. Pendleton Charitable Trust, Diksha and Divesh Makan, Kimberly and Stephen Richardson, Pamela and Edward Taft, and the Skoll Foundation. This work was made possible by a generous gift from an anonymous private donor in support of the ANCeR diagnostics consortium. These funders played no role in study design, data collection and analysis, writing the manuscript, or decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board at University of California, San Francisco approved this study under IRB #17-24056.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is presented as such in the results, methods, or supplement.